Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial investigating the effect of entrectinib (RXDX-101) in solid tumours

Next Previous
Trial Profile

A phase I/II trial investigating the effect of entrectinib (RXDX-101) in solid tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors Ignyta

    • Most Recent Events

    • 01 Feb 2024 Results of updated data cohort of patients with NTRK fusion-positive (fp) NSCLC (objective response rate [ORR]: 64.5 %; 2 August 2021 data cut-off) from three phase I/II studies (ALKA-372-001: EudraCT 2012-000148-88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267) assessing efficacy in patients with NTRK fusion-positive (fp) NSCLC published in the Lung Cancer.
    • 12 Sep 2023 Results assessing Individual patient data (IPD) from entrectinib trials (ALKA-372-001/EudraCT 2012-000148-88, STARTRK-1/NCT02097810 and STARTRK-2/NCT02568267) and aggregate data from a crizotinib trial (OxOnc/NCT01945021) using unanchored matching adjusted indirect comparison, presented at the 24th World Conference on Lung Cancer.
    • 06 Jun 2023 Results of updated data from EudraCT, 201200014888, NCT02097810, NCT02568267 presented at the 59th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top